^
    8ms
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Enterome | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    over2years
    A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL (EHA 2022)
    Results The safety lead-in dose-finding is currently ongoing, and no safety concerns have been observed thus far. Conclusion This is a first in human clinical trial to evaluate safety, determine the recommended phase 2 dose and estimate efficacy of a novel microbial-derived peptide therapeutic vaccine, EO2463, in patients with indolent non-hodgkin lymphoma as monotherapy and in combination with lenalidomide and rituximab.
    Clinical • P1/2 data • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    3years
    An early phase clinical trial to investigate EO2463, a novel cancer vaccinetherapy, in patients with indolent Non-Hodgkin's Lymphoma. Sperimentazione clinica di fase iniziale per studiare EO2463, una nuova terapia antitumorale a base di vaccino in pazienti con Linfoma non Hodgkin indolente. (clinicaltrialsregister.eu)
    P1/2, N=54, Ongoing, ENTEROME
    Clinical • New P1/2 trial • Combination therapy
    |
    IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    over3years
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Enterome | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    IFNG (Interferon, gamma)
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    almost4years
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Enterome
    Clinical • New P1/2 trial • Combination therapy
    |
    IFNG (Interferon, gamma)
    |
    Rituxan (rituximab) • lenalidomide • EO2463